ReviewProceedings of the American Thoracic Society2007
The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research.
Review in Proceedings of the American Thoracic Society, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 87 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Innate and Adaptive Immunity in COPD Exacerbations: Bronchoscopies on Healthy Volunteers
Innate and Adaptive Immunity in COPD Exacerbations: Prospective Cohort Study
Innate and Adaptive Immunity in COPD Exacerbations: Surgical Volunteers
Innate and Adaptive Immunity in COPD Exacerbations: Severe AE-COPD Clinical Course Study
Investigating the Association Between Altered Lung MicroBiome and HIV-associated Chronic Obstructive Pulmonary Disease in a Ugandan Cohort
Who cites it
87 citing papers in PubMed, 1 synthesis or guideline pooled it, 186 citations in OpenAlex.
- Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis.International journal of chronic obstructive pulmonary disease · 2016Pooled it
- Trial
- Trial
- Emerging role of SIRT1 in asthma and COPD from molecular mechanisms to translational therapy.iScience · 2026Review
- lncRNALife science alliance · 2025Article
- Chitinase 3-like-1 Inhibits Innate Antitumor and Tissue Remodeling Immune Responses by Regulating CD47-SIRPα- and CD24-Siglec10-Mediated Phagocytosis.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Article
- Protease-armed, Pathogenic Extracellular Vesicles Link Smoking and Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2023Article
- Antiviral CD8The European respiratory journal · 2023Article
- Understanding COPD Etiology, Pathophysiology, and Definition.Respiratory care · 2023Article
- Welcome to the Neighborhood: Tissue-Resident Lung Natural Killer Cells in Chronic Obstructive Pulmonary Disease and Viral Infections.American journal of respiratory and critical care medicine · 2023Article
- Characteristics of Serum Autoantibody Repertoire and Immune Subgroup Variation of Tuberculosis-Associated Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2023Article
- Chronic Obstructive Pulmonary Disease and Cigarette Smoke Lead to Dysregulated Mucosal-associated Invariant T-Cell Activation.American journal of respiratory cell and molecular biology · 2023Article
- Review
- Health-Screening-Based Chronic Obstructive Pulmonary Disease and Its Effect on Cardiovascular Disease Risk.Journal of clinical medicine · 2022Article
- Yijin-Tang Attenuates Cigarette Smoke and Lipopolysaccharide-Induced Chronic Obstructive Pulmonary Disease in Mice.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Small airway determinants of airflow limitation in chronic obstructive pulmonary disease.Thorax · 2021Article
- Article
- A Robust Protocol for Decellularized Human Lung Bioink Generation Amenable to 2D and 3D Lung Cell Culture.Cells · 2021Article
- The effects of BAFF on T lymphocytes in chronic obstructive pulmonary disease.Respiratory research · 2020Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Chronic obstructive pulmonary disease (COPD) progression is characterized by accumulation of inflammatory mucous exudates in the lumens of small airways, and thickening of their walls, which become infiltrated by innate and adaptive inflammatory immune cells. Infiltration of the airways by polymorphonuclear and mononuclear phagocytes and CD4 T cells increases with COPD stage, but the cumulative volume of the infiltrate does not change. By contrast, B cells and CD8 T cells increase in both the extent of their distribution and in accumulated volume, with organization into lymphoid follicles. This chronic lung inflammation is also associated with a tissue repair and remodeling process that determines the ultimate pathologic phenotype of COPD. Why these pathologic abnormalities progress in susceptible individuals, even after removal of the original noxious stimuli, remains mysterious. However, important clues are emerging from analysis of pathologic samples from patients with COPD and from recent discoveries in basic immunology. We consider the following relevant information: normal limitations on the innate immune system's ability to generate adaptive pulmonary immune responses and how they might be overcome by tobacco smoke exposure; the possible contribution of autoimmunity to COPD pathogenesis; and the potential roles of ongoing lymphocyte recruitment versus in situ proliferation, of persistently activated resident lung T cells, and of the newly described T helper 17 (Th17) phenotype. We propose that the severity and course of acute exacerbations of COPD reflects the success of the adaptive immune response in appropriately modulating the innate response to pathogen-related molecular patterns ("the Goldilocks hypothesis").
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.